Loading
What changed between revision 1 and revision 2, compared over the article's markdown source with its frontmatter — so a change to status, evidence or reversibility shows up as the edit it is.
Older · revision 1
Import· initial corpus import, not an edit
Initial import of content/epigenome-editing.md — the filesystem corpus, unchanged. Not an edit.
12.5 kB
Revision 1
Revision 2
lines 8–14 → 8–147 unchanged lines not shown
categories: ["genetics"]categories: ["genetics"]tags: ["crispr", "epigenetics", "gene regulation", "gene therapy", "dna methylation", "biotechnology"]tags: ["crispr", "epigenetics", "gene regulation", "gene therapy", "dna methylation", "biotechnology"]summary: "Targeted modification of the chemical marks that control gene expression, switching a gene off or on without altering the underlying DNA sequence."summary: "Targeted modification of the chemical marks that control gene expression, switching a gene off or on without altering the underlying DNA sequence."updated: "2026-07-27"updated: "2026-10-29"humanEvidence: "Early-phase trials in chronic hepatitis B and facioscapulohumeral muscular dystrophy are reported to have dosed patients in 2024 and 2025, with no published results; the year-long silencing results are from mice."humanEvidence: "Early-phase trials in chronic hepatitis B and facioscapulohumeral muscular dystrophy are reported to have dosed patients in 2024 and 2025, with no published results; the year-long silencing results are from mice."access: "Not obtainable outside company-run clinical trials; no epigenetic editor has been approved by any regulator."access: "Not obtainable outside company-run clinical trials; no epigenetic editor has been approved by any regulator."reversibility: "context"reversibility: "context"lines 24–36 → 24–369 unchanged lines not shown
{ "label": "First demonstrated", "value": "2013 (dCas9 repression)" }, { "label": "First demonstrated", "value": "2013 (dCas9 repression)" }, { "label": "Changes DNA sequence", "value": "No" }, { "label": "Changes DNA sequence", "value": "No" }, { "label": "Durability", "value": "Locus-dependent" }, { "label": "Durability", "value": "Locus-dependent" }, { "label": "First human trials", "value": "2024–2025" }, { "label": "First human trials", "value": "2024-2025" }, { "label": "Readiness", "value": "TRL 6" } { "label": "Readiness", "value": "TRL 6" } ] ]}}`````` **Epigenome editing** changes how much of a gene a cell makes without changing the gene itself. A programmable DNA-binding protein is aimed at a promoter or enhancer and carries with it an enzyme that writes or erases a regulatory mark — DNA methylation, histone modification — or that simply recruits the cell's own repression machinery. The sequence is left intact, which means the change is in principle reversible, and which also means it can be lost. That distinguishes it sharply from [[base-editing]] and [[prime-editing]], which alter the genome permanently and cannot be undone once installed.**Epigenome editing** changes how much of a gene a cell makes without changing the gene itself. A programmable DNA-binding protein is aimed at a promoter or enhancer and carries with it an enzyme that writes or erases a regulatory mark (DNA methylation, histone modification) or that simply recruits the cell's own repression machinery. The sequence is left intact, which means the change is in principle reversible, and which also means it can be lost. That distinguishes it sharply from [[base-editing]] and [[prime-editing]], which alter the genome permanently and cannot be undone once installed. ## How it works## How it works lines 48–99 → 48–9911 unchanged lines not shown
- **Activators.** Transcriptional activation domains, alone or in multiplexed arrays, raise expression from a silent or weakly expressed locus. Histone acetyltransferase fusions open chromatin at enhancers rather than acting on the promoter directly.- **Activators.** Transcriptional activation domains, alone or in multiplexed arrays, raise expression from a silent or weakly expressed locus. Histone acetyltransferase fusions open chromatin at enhancers rather than acting on the promoter directly.- **Erasers.** Demethylases remove existing methylation and can reactivate a silenced gene, which is the basis of most reversibility claims.- **Erasers.** Demethylases remove existing methylation and can reactivate a silenced gene, which is the basis of most reversibility claims. The distinction that matters clinically is between effects that persist only while the editor is present and effects that persist after it is gone. Simple repressor fusions do the former. Combining a KRAB domain with methyltransferases produces silencing that survives cell division and differentiation after a single transient exposure — the property that turned epigenome editing from a laboratory technique into a therapeutic proposition.[^nunez2021]The distinction that matters clinically is between effects that persist only while the editor is present and effects that persist after it is gone. Simple repressor fusions do the former. Combining a KRAB domain with methyltransferases produces silencing that survives cell division and differentiation after a single transient exposure.[^nunez2021] That property turned epigenome editing from a laboratory technique into a therapeutic proposition. ```timeline```timeline[[ { "year": "2013", "title": "Programmable repression", "text": "Several groups show that catalytically dead Cas9, alone or fused to a KRAB repressor domain, can silence a targeted gene in bacteria and in human cells." }, { "year": "2013", "title": "Programmable repression", "text": "Several groups show that catalytically dead Cas9, alone or fused to a KRAB repressor domain, can silence a targeted gene in bacteria and in human cells." }, { "year": "2015–2016", "title": "Writers and erasers", "text": "Fusions to histone acetyltransferase, DNA methyltransferase and TET demethylase domains demonstrate direct editing of regulatory marks at chosen loci." }, { "year": "2015-2016", "title": "Writers and erasers", "text": "Fusions to histone acetyltransferase, DNA methyltransferase and TET demethylase domains demonstrate direct editing of regulatory marks at chosen loci." }, { "year": "2016", "title": "Hit-and-run silencing", "text": "Transient delivery of combined repressor and methyltransferase effectors is shown to produce inheritable silencing of endogenous genes in cultured cells." }, { "year": "2016", "title": "Hit-and-run silencing", "text": "Transient delivery of combined repressor and methyltransferase effectors is shown to produce inheritable silencing of endogenous genes in cultured cells." }, { "year": "2021", "title": "Single-construct memory", "text": "A single fusion protein is shown to install durable, reversible transcriptional silencing at a large fraction of the genome's promoters." }, { "year": "2021", "title": "Single-construct memory", "text": "A single fusion protein is shown to install durable, reversible transcriptional silencing at a large fraction of the genome's promoters." }, { "year": "2024", "title": "Durable silencing in animals", "text": "A single in vivo dose targeting a cholesterol-regulating gene produces silencing lasting many months in mice." }, { "year": "2024", "title": "Durable silencing in animals", "text": "A single in vivo dose targeting a cholesterol-regulating gene produces silencing lasting many months in mice." }, { "year": "2024–2025", "title": "First patients", "text": "Epigenetic silencing candidates for chronic hepatitis B and for facioscapulohumeral muscular dystrophy are reported dosed in early-phase trials." } { "year": "2024-2025", "title": "First patients", "text": "Epigenetic silencing candidates for chronic hepatitis B and for facioscapulohumeral muscular dystrophy are reported dosed in early-phase trials." }]]`````` ## Development history## Development history The tools arrived in a predictable order: repression first, because recruiting existing silencing machinery is easy;[^gilbert2013] activation next, because it needed multiplexed activation domains to reach useful expression levels; and durable, heritable marks last, because those required combining several enzymatic activities at once.[^liu2016] The pivotal demonstration for medicine was that a transient dose could leave a permanent regulatory state — a "hit-and-run" edit — since a therapy that requires continuous expression of a bacterial protein is difficult to make safe.[^amabile2016]The tools arrived in a predictable order: repression first, because recruiting existing silencing machinery is easy;[^gilbert2013] activation next, because it needed multiplexed activation domains to reach useful expression levels; and durable, heritable marks last, because those required combining several enzymatic activities at once.[^liu2016] The demonstration that mattered for medicine was that a transient dose could leave a permanent regulatory state, a "hit-and-run" edit, since a therapy that requires continuous expression of a bacterial protein is difficult to make safe.[^amabile2016] Work in mice then showed that a single systemic dose could silence a liver gene for the better part of a year without touching the DNA sequence.[^cappelluti2024] That result, together with the observation that reversal is possible with a demethylating editor, defined the commercial pitch: the durability of gene therapy with an off switch.Work in mice then showed that a single systemic dose could silence a liver gene for the better part of a year without touching the DNA sequence.[^cappelluti2024] That result, together with the observation that reversal is possible with a demethylating editor, defined the commercial pitch: the durability of gene therapy with an off switch. ## Current state## Current state As of 2026 the field has moved into first-in-human testing, with results still limited. Several venture-funded companies pursue durable epigenetic silencing — one focused on chronic hepatitis B, where the aim is to silence both the viral episome and integrated viral DNA that antivirals cannot clear; another on facioscapulohumeral muscular dystrophy, where the disease is caused by inappropriate expression of a normally silent gene and where restoring silence is a more natural fix than cutting. Zinc-finger repressors have been developed for chronic pain and for prion disease, where lowering expression of a single protein is the whole therapeutic goal, though how far each has advanced into human testing is not firmly established. None of these has produced anything comparable to the approval record of nuclease-based [[somatic-gene-therapy]], and no epigenetic editor has reached the regulatory stage of [[casgevy]].As of 2026 the field has moved into first-in-human testing, with results still limited. Several venture-funded companies pursue durable epigenetic silencing. One is focused on chronic hepatitis B, where the aim is to silence both the viral episome and integrated viral DNA that antivirals cannot clear; another on facioscapulohumeral muscular dystrophy, where the disease is caused by inappropriate expression of a normally silent gene and where restoring silence is a more natural fix than cutting. Zinc-finger repressors have been developed for chronic pain and for prion disease, where lowering expression of a single protein is the whole therapeutic goal, though how far each has advanced into human testing is not firmly established. None of these has produced anything comparable to the approval record of nuclease-based [[somatic-gene-therapy]], and no epigenetic editor has reached the regulatory stage of [[casgevy]]. Consolidation has been rapid. Companies in the sector have merged or refocused since 2024, and the small number of programmes in the clinic means that a single safety event would change the field's trajectory. Readers should treat any specific programme status here as possibly outdated.Consolidation has been rapid. Companies in the sector have merged or refocused since 2024, and the small number of programmes in the clinic means that a single safety event would change the field's trajectory. Readers should treat any specific programme status here as possibly outdated. > [!key] Why silencing is the natural first target> [!key] Why silencing is the natural first target> For a large class of diseases the problem is too much of something — a viral genome, a toxic protein, a gene that should be off. Turning expression down requires no template, no repair pathway and no correction of a specific mutation, so one editor can serve every patient with the condition regardless of their individual genotype.> For a large class of diseases the problem is too much of something: a viral genome, a toxic protein, a gene that should be off. Turning expression down requires no template, no repair pathway and no correction of a specific mutation, so one editor can serve every patient with the condition regardless of their individual genotype. ## Limitations## Limitations Durability is locus-dependent and imperfectly predictable. Promoters rich in CpG dinucleotides accept and propagate methylation well; CpG-poor promoters often do not, and some loci resist stable silencing entirely. Activation is harder than repression: raising a gene's output to a therapeutically meaningful, sustained level is much less reliable than shutting it down, which is why activation-based programmes lag repression-based ones.Durability is locus-dependent and imperfectly predictable. Promoters rich in CpG dinucleotides accept and propagate methylation well; CpG-poor promoters often do not, and some loci resist stable silencing entirely. Activation is harder than repression: raising a gene's output to a therapeutically meaningful, sustained level is much less reliable than shutting it down, which is why activation-based programmes lag repression-based ones. Delivery imposes the same constraints as elsewhere in the field. The fusion proteins are large — larger than Cas9 alone — so single-vector packaging in [[aav-vectors]] is often impossible, and most in vivo work uses [[lipid-nanoparticles]] carrying messenger RNA, which mainly reaches the liver. Repeat dosing, if durability proves shorter than hoped, would run into anti-Cas9 immunity.Delivery imposes the same constraints as elsewhere in the field. The fusion proteins are large, larger than Cas9 alone, so single-vector packaging in [[aav-vectors]] is often impossible, and most in vivo work uses [[lipid-nanoparticles]] carrying messenger RNA, which mainly reaches the liver. Repeat dosing, if durability proves shorter than hoped, would run into anti-Cas9 immunity. ## Risks## Risks Because dCas9 binds tolerantly at sequences that would not be cut, epigenome editors can perturb transcription at sites where a nuclease would produce no [[crispr-off-target-effects|off-target lesion]] at all. Off-target binding is transient and reversible in principle, but if the effector deposits durable methylation the perturbation may not be. Silencing can also spread beyond the intended element to neighbouring genes, and long-range enhancer contacts mean the affected gene is not always the nearest one.Because dCas9 binds tolerantly at sequences that would not be cut, epigenome editors can perturb transcription at sites where a nuclease would produce no [[crispr-off-target-effects|off-target lesion]] at all. Off-target binding is transient and reversible in principle, but if the effector deposits durable methylation the perturbation may not be. Silencing can also spread beyond the intended element to neighbouring genes, and long-range enhancer contacts mean the affected gene is not always the nearest one. A structural concern is verification. Sequencing shows that the genome is unchanged, which is reassuring but also means the standard safety assay is blind to the edit. Confirming that an epigenetic therapy did what was intended, and nothing else, requires genome-wide methylation and expression profiling of the treated tissue — feasible in a mouse, difficult in a patient.A structural concern is verification. Sequencing shows that the genome is unchanged, which is reassuring but also means the standard safety assay is blind to the edit. Confirming that an epigenetic therapy did what was intended, and nothing else, requires genome-wide methylation and expression profiling of the treated tissue, which is feasible in a mouse and difficult in a patient. > [!caution] Reversibility is a design goal, not a guarantee> [!caution] Reversibility is a design goal, not a guarantee> Erasing an installed mark has been demonstrated in cultured cells and in animals. Whether a clinician could reliably reverse a silencing therapy in a patient, in the tissue where it was delivered, has not been shown.> Erasing an installed mark has been demonstrated in cultured cells and in animals. Whether a clinician could reliably reverse a silencing therapy in a patient, in the tissue where it was delivered, has not been shown. ## Relation to reprogramming and aging## Relation to reprogramming and aging Epigenome editing is often confused with [[epigenetic-reprogramming]], which uses [[yamanaka-factors|pluripotency transcription factors]] to reset a cell's epigenome globally rather than at a chosen locus. The two share a premise — that cell state is written in modifiable marks — and little else. Targeted editing changes one element and leaves identity alone; [[partial-reprogramming]] changes identity and leaves the specific targets unchosen. Companies such as [[newlimit]] work between the two, screening transcription factor combinations for effects on cell state rather than editing single regulatory elements, and readings from an [[epigenetic-clock]] are sometimes used as an outcome measure in both approaches despite the unresolved question of what such clocks actually track.Epigenome editing is often confused with [[epigenetic-reprogramming]], which uses [[yamanaka-factors|pluripotency transcription factors]] to reset a cell's epigenome globally rather than at a chosen locus. The two share a premise, that cell state is written in modifiable marks, and little else. Targeted editing changes one element and leaves identity alone; [[partial-reprogramming]] changes identity and leaves the specific targets unchosen. Companies such as [[newlimit]] work between the two, screening transcription factor combinations for effects on cell state rather than editing single regulatory elements, and readings from an [[epigenetic-clock]] are sometimes used as an outcome measure in both approaches despite the unresolved question of what such clocks actually track. ## Outlook## Outlook removed, struck through added, underlinedLine numbers count the serialised markdown of each revision, frontmatter included.
108 lines are the same in both revisions, and 48 of them are not shown. Neither revision here is necessarily the current article — read Epigenome editing for the text this wiki stands behind today.